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Abstract
Background: The development and evaluation of new therapeutic approaches for malignant mesothelioma has
been sparse due, in part, to lack of suitable tumor models.
Methods: We established primary mesothelioma cultures from pleural and ascitic fluids of five patients with advanced
mesothelioma. Electron microscopy and immunohistochemistry (IHC) confirmed their mesothelial origin. Patient derived
xenografts were generated by injecting the cells in nude or SCID mice, and malignant potential of the cells was
analyzed by soft agar colony assay. Molecular profiles of the primary patient tumors, early passage cell cultures,
and patient derived xenografts were assessed using mutational analysis, fluorescence in situ hybridization (FISH)
analysis and IHC.
Results: Primary cultures from all five tumors exhibited morphologic and IHC features consistent to those of mesothelioma
cells. Mutations of BAP1 and CDKN2A were each detected in four tumors. BAP1 mutation was associated with the lack
of expression of BAP1 protein. Three cell cultures, all of which were derived from BAP1 mutant primary tumors, exhibited
anchorage independent growth and also formed tumors in mice, suggesting that BAP1 loss may enhance tumor
growth in vivo. Both early passage cell cultures and mouse xenograft tumors harbored BAP1 mutations and CDKN2A
deletions identical to those found in the corresponding primary patient tumors.
Conclusions: The mesothelioma patient derived tumor xenografts with mutational alterations that mimic those
observed in patient tumors which we established can be used for preclinical development of novel drug regimens
and for studying the functional aspects of BAP1 biology in mesothelioma.
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Background
Malignant mesothelioma is an asbestos-related aggressive
tumor with poor prognosis, occurring in the mesothelial
lining of pleural or peritoneal cavities. Malignant meso-
thelioma is a deadly and clinically challenging disease due
to its low incidence, resistance to most chemotherapies,
and complexity of tumor anatomy. Despite multimodality
therapy, the median overall survival is less than a year for
patients with pleural tumors, and the 5-year survival rate is
less than 15% for peritoneal mesothelioma [1].
The development and evaluation of new therapeutic
approaches for malignant mesothelioma has been sparse
due, in part, to lack of suitable tumor models. Efforts to
generate clinically relevant tumor models have focused
on two main approaches in the recent years: generation
of primary tumor-derived cell lines and of mouse
models. Primary tumor-derived cell lines have adapted
to growth outside a natural tumor microenvironment
and due to selective processes associated with long term
culturing will develop genetic changes that are distinct
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from the genetic stress imposed on tumors in patients
[2-4]. Therefore even when propagated in vivo, they may
not be suitable for preclinical testing of anti-cancer drugs
or for studying the underlying gene expression associated
with novel drug responses. Mouse models generated via
engraftment of primary human tumors into immune-
compromised mouse models have become increasingly
popular for preclinical testing of anticancer drugs. How-
ever their usefulness depends upon the preservation of
biological and morphological characteristics of the pri-
mary tumors [5]. Many of the currently available meso-
thelioma cell lines do not form tumors in mice, and others
have been propagated in culture for many passages, lead-
ing to various cytogenetic changes. Thus, these lines often
do not show much similarity with the original tumors [6].
The most common genetic alterations associated with
mesothelioma, including CDKN2A deletions and NF2mu-
tations, have been known for about two decades [7-9].
More recently, mutations in the BAP1 tumor suppressor
gene have been observed in 20-25% of mesothelioma
tumor samples [10,11]. BAP1, a nuclear ubiquitin hydro-
lase, plays an important role in various cellular processes
including cell proliferation, DNA repair and regulation of
gene expression at the chromatin level [12].
This study describes molecular and immunohistochemi-
cal characterization of five primary mesothelioma cell
lines. By comparing mutational and immunohistochemical
profiles between primary cell cultures, and patient derived
xenografts, we report the stability of both the genetic pro-
file and protein expression in the xenografts, highlighting
their potential for exploring genetic changes associated
with responses to established and novel drugs.
Methods
Pathological examination of the original tumor specimens
All patients whose samples were utilized for this study
were enrolled in Institutional Review Board approved
protocols at the Center for Cancer Research, National
Cancer Institute. All patients provided written informed
consent which allowed the storage and use of body
fluids, tumor samples and data that were collected for
future research. Tumor samples obtained from five pa-
tients at the time of diagnosis or at the time of debulking
surgery were evaluated by a pathologist to establish the
diagnosis and characterize the subtype of mesothelioma.
Establishment of early-passage mesothelioma cell
cultures
Early passage primary mesothelioma cell cultures were iso-
lated from ascites or pleural fluid obtained from mesotheli-
oma patients at the National Cancer Institute. The ascites
or pleural fluid (100–1000 mL) was centrifuged at
1000 rpm at room temperature for 3 minutes; the cell pel-
lets were washed twice with phosphate buffered saline
(PBS), and red blood cells were removed using a BD Pharm
Lyse™-Lysing Buffer kit (BD Bioscience, NJ), according to
the manufacturer’s instructions, and washed again two
times with PBS. The cells were then resuspended in RPMI
1640 (Invitrogen, CA) supplemented with 2 mM glutam-
ine, 100 units penicillin-streptomycin, and 1 mM sodium
pyruvate (each from Invitrogen, CA) plus 20% fetal bovine
serum (FBS) (Lonza, MD). The cells were seeded into
175 mL culture flasks at a density of 2.5-4.0 × 105 cells/ml.
After incubating at 37°C in a humidified, 5% CO2 atmos-
phere overnight, the medium containing non-adherent
cells was replaced with fresh medium. The cultures were
maintained by changing the medium depending upon the
growth of the cells. To authenticate these cell lines for fu-
ture use by us or other investigators we performed Short
Tandem Repeats (STR) analysis of these cells.
Immunohistochemistry
Cells were detached using trypsin-EDTA and then washed
and centrifuged. The cell pellets were fixed in formalin
and embedded in paraffin. Tumor sections were prepared,
and immunohistochemical studies were carried out for
the mesothelial markers calretinin, WT1, CK5/6, and
mesothelin and BAP1 using specific antibodies (Santa
Cruz Biotechnology, TX). All immunostaining was carried
out using an automated Ventana system (Ventana Medical
Systems, AZ) using their UltraView polymer based detec-
tion system. IHC staining was scored semiquantitatively as
follows: negative (less than 5% of cells stained), 1+ positive
(5- 50%), and 2+ positive (50-100%).
Electron microscopy
Cells from all five cell lines were washed in PBS, fixed in
PBS-buffered 2.5% glutaraldehyde (Sigma Chemicals,
MO), postfixed in 0.5% osmium tetroxide and embedded
into Spurr’s epoxy resin (Ladd Research Industries, VT).
Ultrathin sections were stained with uranyl acetate-lead
citrate and viewed in a Phillips CM10 transmission elec-
tron microscope.
Spectral karyotyping and fluorescent in situ hybridization
Spectral karyotyping was performed according to the
manufacturer’s protocol using 24-color human SKY paint
probes (Applied Spectral Imaging, CA). Fluorescent in
Situ Hybridization (FISH) analysis was carried out using a
CDKN2A probe (Abbott Molecular, IL) encompassing the
overlapping genes encoding p16INK4a and p14ARF. Spectral
images of the hybridized metaphases were acquired using
a SD301 SpectraCubeTM system (Applied Spectral Im-
aging Inc., CA) mounted on top of an epi-fluorescence
microscope Axioplan 2 (Zeiss). Images were analyzed
using Spectral Imaging 6.0 acquisition software (Applied
Spectral Imaging Inc., CA). At least 10 SKY hybridized
metaphases were analyzed in this experiment. FISH
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analyses were performed under an Axioplan 2 (Zeiss)
fluorescence microscope coupled with a CCD camera
(ASI) and images were captured with FISH view 5.5 soft-
ware (Applied Spectral Imaging Inc., Vista, CA).
Mutation analysis
Genomic DNA was extracted from early passage cells using
a DNA isolation kit (Mo-Bio Laboratories, CA). PCR was
done using exon specific primers for the entire coding region
of BAP1, the tyrosine kinase domain of the EGFR, [13] and
exons 2–9 of TP53. Polymerase Chain Reaction (PCR) prod-
ucts were purified and subjected to Sanger sequencing on an
ABI PRISM sequencing apparatus (ABI Prism 310 Genetic
Analyser, Applied Biosystems, NY). In addition, a panel of
hotspot mutations in 7 genes (AKT1, BRAF, EBRR2, EGFR,
KRAS, NRAS, and PIK3CA) was analyzed with pyrosequenc-
ing for single-nucleotide variants (SNVs) or with fragment
analysis for insertions/deletions (indels). Briefly PCR amplifi-
cation was initially performed with primers flanking the mu-
tation hotspot under co-amplification at lower denaturation
temperature (COLD)-PCR conditions and was followed by
targeted pyrosequencing on a PyroMark Q24 instrument
(Qiagen) or by capillary electrophoresis using a Genetic
Analyzer 3130xl (Life Technologies) [14-20].
Flow cytometry
Mesothelin expression on early and late passage primary
cell cultures were evaluated by flow cytometry using the
anti-mesothelin primary antibody (MN) as previously
described [21].
Western blotting
Monolayers of confluent cells were washed twice in PBS and
then lysed in 1× Cell Lysis Buffer supplemented with 1 mM
phenylmethylsulfonylfluoride (Cell Signaling Technology,
MA). Fifty micrograms of total protein were subjected to
SDS-polyacrylamide gel electrophoresis (Invitrogen, CA) for
each cell line followed by immunoblotting with mouse
monoclonal E-cadherin, N-cadherin and vimentin anti-
bodies (BD Bioscience, NJ) and BAP1 antibody (Santa
Cruz Biotechnology, CA) (1:1,000 in 5% blocking reagent
in Tris-buffered saline/Tween-20) overnight at 4°C. The
following day, blots were incubated with goat anti-mouse
IgG conjugated with horseradish peroxidase (Santa Cruz
Biotechnology; 1:1,000 dilution) for 1 hour at 25°C. Signals
were visualized with enhanced chemiluminescence re-
agent (Amersham Pharmacia Biotech, NJ) on X-ray film
(Eastman Kodak, NY).
Soft agar colony assay
Twenty thousand cells were suspended in 0.3% low melting
agarose (Lonza, Rockland, ME) in RPMI containing 20%
FBS. This suspension was overlaid onto a solid layer of
0.6% agarose in a 6-well plate. The cells were treated with
fresh RPMI containing 20% FBS every other day. After 2–3
weeks, depending upon the growth, the cells were fixed
with methanol, stained with 0.02% crystal violet, and photo-
graphed at ×10 magnification.
In vivo xenograft studies
All animal experiments were performed in accordance
with NIH guidelines and approved by the NCI Animal
Care and Use Committee. Cultured cells (5×106-10×106
cells) were injected subcutaneously into the dorsal side
of three nude or SCID mice. The animals were examined
every week for the development of tumors. All animal
care was done in accordance with institutional guide-
lines. The single tumor for each primary cell was excised
and fixed in 10% formalin to process for routine histo-
pathological examination and to perform immunohisto-
chemical staining for the earlier mentioned markers.
Results
Primary mesothelioma cultures established from
malignant effusions of patients with mesothelioma
Table 1 summarizes characteristics, diagnosis and course of
treatment of patients with malignant mesothelioma from
whom the primary cultures were derived. Four of the five
tumors had epithelial histology and one was predominantly
epithelial with focal sarcomatous features. All tumors were
positive (15-100% of tumor cells) for mesothelioma-related
markers mesothelin and calretinin by IHC. Four of the tu-
mors were also positive for the cytokeratin 5/6.
Morphologic features, electron microscopy and
immunohistochemical staining of primary cell cultures are
indicative of their being of mesothelial origin
Primary cultures from all five tumors exhibited morpho-
logic and immunohistochemical features consistent to
those of mesothelial cells. All primary cultures except
NCI-Meso17 grew as adherent monolayers characterized
by polygonal epithelial-type cells that tended to group to-
gether as clusters in a colony-like formation. In addition
to polygonal epithelial cells, NCI-Meso17 cells also in-
cluded spindle like cells, which became the predominant
cell population as the cells were maintained in culture.
Cell blocks were prepared from early-passage (≤5 pas-
sages) mesothelioma cells and sections were evaluated by
hematoxylin and eosin (H&E) and IHC (Figure 1 and
Table 1). IHC revealed high levels of expression of
mesothelin (2+ to 3+), and WT1 and calretinin (3+) in
three samples (NCI-Meso16, NCI-Meso19, NCI-Meso21).
NCI-Meso17, which was derived from a patient who had
biphasic disease, was negative for most of the above
markers, but retained a few WT-1 positive cells. NCI-
Meso18, which was derived from an epithelioid mesotheli-
oma, retained moderate expression of calretinin and
minimal expression of mesothelin and WT1.
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Electron microscopy analysis further supported the
mesothelial origin of these cells, as the long irregular
and branched microvilli characteristic of mesothelioma
cells were present in all the cell cultures (Figure 1). We
also noticed the presence of intracytoplasmic intermedi-
ate filaments in all the primary cells and glycogen bodies
in some of them. Tonofilaments could also be seen in
one of the cell cultures (NCI-Meso21). Thus, the elec-
tron microscopy data strongly indicated that the primary
cell cultures are of mesothelioma origin.
The cell morphology was retained throughout the 30
passages we tested, and we performed STR analysis at dif-
ferent passages in order to eliminate the possibility of cross
contamination among cell cultures (Additional file 1).
STR analysis showed only modest changes in DNA finger-
printing profiles between primary tumors and the corre-
sponding cell cultures [22]. We also assessed cell surface
expression of mesothelin by flow cytometry in early and
late passage cells (Additional file 2). Primary cells which
expressed mesothelin at early passages (NCI-Meso16,
NCI-Meso18, NCI-Meso19, and NCI-Meso21) continued
to express mesothelin in late passage cultures. NCI-
Meso17 which did not express mesothelin in early passages
remained mesothelin negative in late passages. Following
thawing, cryopreserved cells could be propagated in cul-
ture without a noticeable change in growth and morph-
ology. In all subsequent experiments, cells were used
between the third to sixth passages in culture.
Cytogenetic analysis reveals abnormal karyotype in all
five primary cultures
Spectral karyotyping of early passage cell cultures un-
covered multiple structural and numerical chromo-
some abnormalities in all five cultures as summarized
Table 1 Clinical and pathological characteristics of patients from which primary cultures were established
Cell lines Sex Age (dx) Ethnicity Diagnosis Patient tumor TNM stage Treatment Survival
from diagnosisHistology Positive markers
NCI-Meso16 M 72 Caucasian Pleural Epithelioid Mesothelin: 2+, 30%,
Calretinin, WT1, CK5/
6(focal)
cT4N1M0 (IV) Cisplatin +
Pemetrexed
(6 cycles) with
SS1P (first two
cycles)
8 months
NCI-Meso17 F 63 Caucasian Peritoneal Predominantly
epitheliod with
focal sarcomatous
features
Mesothelin: 2+, 15%,
WT1, CK5/6, CA125
NA Debulking + IP
Cisplatin +
doxorubicin
8 years
IP Pemetrexed + IV
Cisplatin
IP Taxol 34 months
Debulking + IP
mitomycin +
doxorubicin
phase II
investigationsl
agent
NCI-Meso18 M 60 Caucasian Pleural Epithelioid Mesothelin: 3+, 100%,
Calretinin, CK5/6, WT1
cT3N0M0 (III) Cisplatin +
Pemetrexed
EPP
Cisplatin +
Pemetrexed
Gemcitabine
Navelbine
phase II
investigational
agent
NCI-Meso19 M 19 African Pleural Epithelioid Mesothelin: 2+, 100%,
Calretinin
T4N3MX (IV) Died before any
specific treatment
3 months
NCI-Meso21 M 66 Caucasian Pleural Epithelioid Mesothelin: 3+, 75%,
WT1, calretinin, CK5/6
T4 (IV) Cisplatin +
Pemetrexed
(6 cycles) with
SS1P (first two
cycles)
13 months
NA, not applicable; IP, intraperitoneal; IV, intravenous; EPP, extra-pleural pneumonectomy. Patient tumor mesothelin expression is reported based on the intensity
of staining (1+ to 3+) and percentage of cells stained (1-100%).
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in Additional file 3. The more frequent chromosomal re-
arrangements included clonal rearrangement or deletions
of chromosomes 1 (4/5 cell cultures), 3 (3/5), 9 (4/5) and
22 (2/5). The karyotype analysis showed a very high num-
ber of structural abnormalities in NCI-Meso19, a cell cul-
ture derived from a mesothelioma of a young patient
harboring a somatic TP53 mutation. These results are con-
sistent with earlier reports showing frequent alterations of
1p, 3p, 9p, and 22 in human mesothelioma specimens and
derived cell lines [23]. To assess the stability of karyotypic
changes, we evaluated karyotypes of early and late passage
cells. This revealed only minor karyotypic changes between
passages which are summarized in Additional file 3.
Epithelial-mesothelial markers are present in all five
primary cell cultures
All five cell cultures expressed N-cadherin, consistent
with their mesothelial origin as described previously [3].
E-cadherin, an epithelial marker, was also expressed in
all cultures except NCI-Meso17, which was derived from
the patient who had biphasic disease. NCI-Meso17 had
high expression of the mesenchymal marker, vimentin
(Additional file 4).
Frequent BAP1 mutations in primary cell cultures
Mutation analysis of early passage cells revealed BAP1
mutations in 4 of 5 cell cultures (Figure 2A and Table 2).
NCI-Meso16 cells had a splice site mutation in intron 4
of BAP1. NCI-Meso17 and NCI-Meso21 had frame shift
mutations at the intron15/exon16 junction and in exon
13 of BAP1 gene, respectively (Table 2 and Figure 2A).
NCI-Meso18 had a large BAP1 deletion. We found a
clear correlation between BAP1 mutation and the ab-
sence of BAP1 protein by IHC (Figure 2B). For western
blot analysis, we used the mesothelioma cell lines NCI-
H28 (harboring a BAP1 nonsense mutation) and NCI-
H2052 (wild type for BAP1) as positive and negative
controls, respectively, for the presence of a BAP1 protein
(Figure 2C). BAP1 protein expression detected by west-
ern blot was preserved after serial passages with late pas-
sage cells showing similar expression patterns as early
Figure 1 Characteristics of the primary mesothelioma cell cultures. Left panel: Hematoxylin and eosin staining of primary cell cultures. Middle
panels: Representative immunohistochemical stains of mesothelioma cell culture pellets that were formalin-fixed and paraffin-embedded. NCI-Meso16,
NCI-Meso19 and NCI-Meso21 cells were strongly and diffusely positive for mesothelin, calretinin and WT1. NCI-Meso18 cells expressed primarily calretinin
in a smaller percentage of cells, whereas NCI-Meso17 cells showed a small percentage of WT-1 positive cells. Right panel: Electron microscopic images
of primary tumor cells which exhibit numerous long and complex surface villi (thick arrows) that are characteristic of mesothelioma cells. The thin arrow
in the electron microscopic image of the NCI-Meso21 cells points to condensed aggregates of intermediate filaments indicative of tonofilamens, shown
in detail at a higher magnification in the inset.
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Figure 2 BAP1 alterations in primary mesothelioma cells. Chromatograms showing BAP1 mutations (A). Arrow in the top panel indicates the location of
mutation. NCI-Meso16 cells had a splice site mutation in intron 4 of BAP1. NCI-Meso17 and NCI-Meso21 had frame shift mutations at the intron15/exon16
junction and in exon 13 of BAP1 gene, respectively. Immunohistochemistry (B) showing lack of expression of BAP1 protein in cells with mutant BAP1. Only
NCI-Meso19 cells which were BAP1 wild-type expressed the BAP1 protein. Western blot (C) showing the expression of BAP1 in primary mesothelioma cells.
For western blot, mesothelioma cell lines NCI-H28 and NCI-H2052 were used as controls for mutant and wild-type BAP1 respectively. A faint BAP1 band
was observed for NCI-Meso17 cells, which exhibits a 5-bp deletion in exon 13. Western blot showing (D) the expression of BAP1 in late passage primary
mesothelioma cells. The faint BAP1 band which was observed for NCI-Meso17 cells in early passage was absent in late passage.
Table 2 Mutations in early passage malignant mesothelioma primary cell cultures
Cell lines CDKN2A deletion BAP1 NF2 TP53 EGFR KRAS NRAS BRAF PIK3 CA ERBB2 AKT1
NCI-Meso16 wt Intron 4 spice site mutation
c.256-2A >G, Hm
Wt Wt Wt Wt Wt Wt Wt Wt Wt
NCI-Meso17 Hm Deletion of CAGAT at intron
15/exon 16 junction. c.
Wt Wt Wt Wt Wt Wt Wt Wt Wt
1984-3_1985delCAGAT
NCI-Meso18 Hm Large deletion Wt Wt Wt Wt Wt Wt Wt Wt Wt
NCI-Meso19 Hm Wt Large deletion *P322S Wt Wt Wt Wt Wt Wt Wt
NCI-Meso21 Hz Homozygous 20 bp deletion
in exon 13. c.
Wt Wt Wt Wt Wt Wt Wt Wt Wt
1302_1321delTGGGCAA
CTGTCAGTGCTGC
All 5 cell lines were analyzed for mutations in BAP1 whole gene, P53 exons 2–9, EGFR Exons 18–24, KRAS and NRAS Codon 12, 13 and 61, BRAF-599-601, PIK3CA
Exon 9 and 20, ERBB2 insertion in Exon 20 and AKT1 codon 17. *TP53 heterozygous mis-sense mutation in codon 322 (P322S, Exon 9), polymorphism codon 72
(P72R, Exon 4). Hm, homozygous. Hz, heterozygous. Wt, wild-type.
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passage cells (Figure 2D). NCI-Meso17 cells which ex-
hibits a 5-bp deletion in exon 13 demonstrated a faint
BAP1 band in early passages which was not detected in
late passage cells.
Frequent deletions of CDKN2A in primary cell cultures
We screened cell cultures for deletions of the CDKN2A
locus in chromosome 9p21 by FISH analysis on primary
cell cultures. Four of the samples were found to have
homozygous deletions of CDKN2A (Table 2), consistent
with rates reported in malignant mesothelioma cells
[7,24-27]. The percentage of nuclei with a homozygous
deletion pattern was more than 60% in four cultures. One
culture had primarily wild type cells, with less than 10% of
cells showing a homozygous deletion of CDKN2A.
Mutations in other genes tested
We also performed sequence analysis of NF2 and TP53,
and hot spot mutation screening for several oncogenes,
as summarized in Table 2. A large deletion in NF2 and a
missense mutation in exon 8 (P322S) of the TP53 gene
were found in one of the primary cultures (Table 2). We
did not see mutations in any of the other genes tested.
In vitro soft agar colony growth of mesothelioma cells
correlates with tumorigenic potential in vivo
A soft agar colony assay was performed to examine anchor-
age independent growth. Three of the five cultures (NCI-
Meso16, NCI-Meso17 and NCI-Meso21) formed colonies
within 3 weeks (Figure 3A). Cells that formed colonies in
the in vitro assay also formed visible tumors in mice within
3–8 weeks. Notably, all three of these cell cultures had
BAP1 mutations. Tumor growth varied among the cell cul-
tures, with a tumor volume of 100 mm3 achieved between
40 to 80 days after inoculation (Figure 3A).
Early passage mesothelioma cells and their tumor
xenografts retain molecular features of human malignant
mesothelioma
The expression of mesothelioma specific immunohisto-
chemical markers in primary cell cultures were pre-
served in the tumor sections from mouse xenografts
(Figure 3B). Furthermore, the xenografts lacked BAP1
expression, as shown by the absence of nuclear staining,
similar to the corresponding primary cells. This finding
was further supported by detection of the identical
BAP1 mutations in tumor xenografts, and the corre-
sponding primary tumor samples and primary cell cul-
tures (Table 3). In addition, xenograft tumors exhibited
the same CDKN2A deletion status as in primary cell cul-
tures, except in one case where most but not all cells
had a homozygous deletion of CDKN2A, whereas the re-
verse was true in the corresponding primary cell culture.
This suggests that the tumor cells with loss of CDKN2A
had a selective growth advantage in vivo. The two
remaining tumor samples completely matched with their
primary cultures for their CDKN2A deletion status, fur-
ther confirming that primary cells obtained from patient’s
malignant effusions have the same genetic alterations as in
the corresponding primary human tumor.
Discussion
There is a need to develop better preclinical tumor models
to evaluate new therapeutic approaches for mesothelioma.
Patient derived tumor xenograft models are increasingly
being recognized as a robust approach for evaluating the
efficacy of novel therapeutic agents, analyzing the process
of tumor progression at the cellular and molecular level,
and for the identification of new therapeutic targets. How-
ever, their utility depends heavily on preservation and sta-
bility of biological and morphological characteristics of the
primary tumors. Confirmation of this stability is crucial in
order to reliably identify molecular responses to treatment
in xenografts which can be extrapolated back to patients.
In this report, we describe the establishment of pri-
mary mesothelioma cultures and patient derived tumor
xenografts with mutational alterations that recapitulate
those in the original patient tumors. We isolated malig-
nant mesothelioma cells from the ascites or pleural effu-
sion of five mesothelioma patients and grew them
successfully in culture. Furthermore, we performed de-
tailed morphologic and molecular characterization of
early passage cultures of these cells and patient derived
tumor xenografts in nude mice and assessed their malig-
nant potential in vitro. Using a number of techniques,
we demonstrated that these cells were of mesothelial ori-
gin and are indeed malignant. Four of the cell lines had
BAP1 mutations. We also showed a strong correlation
between the mutation and the absence of expression of
BAP1 protein. Three out of five cells, all of which were
derived from BAP1 mutant primary tumors, exhibited
anchorage independent growth and also formed tumors
in vivo, suggesting that BAP1 loss may enhance tumor
growth in vivo. Both early passage cell cultures and
mouse xenograft tumors harbored the BAP1 mutations
and CDKN2A deletions identical to those observed in
the corresponding primary tumor. Given the similarities
to the primary tumor, these models offer an opportunity
in mesothelioma to study efficacy of novel therapeutic
agents and to identify molecular responses to treatment.
We believe these models would also enable further stud-
ies into functional aspects of BAP1, which is mutated in
nearly a quarter of all mesotheliomas.
We also found a strong correlation between the ability
of these cells to grow in an anchorage independent fash-
ion in vitro and to induce tumors in vivo, similar to other
work [6]. These features, along with the stable nature of
these cell cultures, suggest that these early passage cells
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Figure 3 Colony-forming ability and tumorigenicity of primary mesothelioma cells. Colony formation in vitro in 0.3% soft agar (A left panel). Colonies
could be seen for NCI-Meso16, NCI-Meso17 and NCI-Meso21 cell cultures, each of which showed BAP1 mutations. Tumorigenic potential of these cell
cultures was also investigated by subcutaneous injection of cells with matrigel in nude or SCID mice. Representative photographs of subcutaneous
tumors derived following injection of NCI-Meso16, NCI-Meso17 and NCI-Meso21 cells is shown (A middle panel) along with the corresponding
tumor growth curves (A right panel). Immunohistochemical staining for different markers showed the same pattern in tumor xenografts as in the
matching primary cell cultures (B).
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would be useful for functional and preclinical studies. It is
noteworthy that the cell cultures that formed colonies
in vitro and tumors in nude mice were cell lines that had
BAP1 mutations. Previous studies of BAP1 have shown
that BAP1 loss promotes colony-forming ability of meso-
thelioma cells, and that re-expression of BAP1 in BAP1-
deficient markedly decreases colony-formation [11].
Combined with the fact that these same cell cultures were
also tumorigenic suggests that BAP1 loss may also en-
hance tumor growth in vivo.
Some BAP1 missense mutations have been shown to
affect the ubiquitin hydrolase activity of its protein prod-
uct; however, splice site mutations cause exon-skipping
leading to aberrant, out-of-frame transcripts [11]. A re-
cent study has suggested that BAP1 inactivation is more
closely associated with the epithelioid subtype of malig-
nant pleural mesothelioma [28]. Consistent with this
possibility, 3 of the 4 cell cultures harboring BAP1 muta-
tions in our study had epithelioid histology. Since the
p16INK4a/p14ARF proteins encoded by the CDKN2A
locus are essential for normal cell cycle control, FISH
analysis of this locus can be useful for the diagnosis of
early-stage mesotheliomas of epithelial type [29]. Our
finding of homozygous CDKN2A deletions in four of five
cultures helps confirm the malignant nature of these
cells. Recent experimental work has documented the im-
portance of this locus to mesothelioma carcinogenesis.
These studies have shown that mice deficient for either
p16Ink4a or p19Arf, the murine homolog of human
p14ARF, have increased susceptibility to asbestos-induced
mesothelioma and that inactivation of both p16Ink4a or
p19Arf cooperate to accelerate asbestos-induced tumori-
genesis [30].
Karyotypic analysis revealed recurrent abnormalities in
the short arm of chromosome 1, consistent with a dele-
tion hotspot previously implicated in mesothelioma
[31,32]. Deletions of chromosome arms 3p, 9p and 22q,
which include the tumor suppressor genes BAP1,
CDKN2A, and NF2, respectively, have all been linked to
mesothelioma. We also identified variable rearrange-
ments of chromosome 10 in all our primary cultures, a
finding that to our knowledge has not been reported
earlier for malignant mesothelioma. Thus, investigations
of the functional significance of these genomic hotspots,
along with the mutational studies, may lead to the iden-
tification of molecular targets for the treatment of this
disease.
Conclusions
In summary, we describe the establishment of primary
mesothelioma cultures and patient derived tumor xeno-
grafts with features that mirror the primary tumors. The
primary cell cultures derived from ascitic or pleural
fluids of patients with mesothelioma are highly tumori-
genic and maintain the histologic and molecular features
of the original tumors when grown in murine models.
To our knowledge this is the first report that compares
the characteristics of the patient’s tumors with the pri-
mary cells and mouse xenograft at the genetic level in
malignant mesothelioma. Given that these primary cul-
tures and patient derived tumor xenograft models recap-
itulate phenotypic and genetic features of the original
primary mesotheliomas, they should prove useful for
preclinical studies of novel drug regimens and for func-
tional studies of BAP1 biology in mesothelioma.
Table 3 Comparison of patient tumors with primary cell culture and with patient derived xenograft in terms of BAP1
mutation and CDKN2A deletion
BAP1 mutation CDKN2A deletion by FISH
Patient
tumor
Primary
cell
culture
Mouse
xenograft
Patient tumor Primary cell
culture
Mouse xenograft
NCI-Meso16 (splice site
mutation in Intron 4)
Present Present Present NCI-Meso16 (wt) Homozygous
deleted cells some
wt cells
Mostly wt. Some
homozygous
deleted cells
Mostly wt. Some
homozygous
deleted cells
NCI-Meso17 (5 bp deletion
in intron 15- Exon 16
junction)
Present Present Present NCI-Meso17
(Homozygous
deletion)
Present Present Present
NCI-Meso18 (large deletion) Sample
not
available
large
deletion
Does not
form
tumor
NCI-Meso18
(Homozygous
deletion)
Sample not
available
Present Does not form
tumor
NCI-Meso19 (Wt) Wt Wt Does not
form
tumor
NCI-Meso19
(Homozygous
deletion)
Present Present Does not form
tumor
NCI-Meso21 (20 bp
deletion in Exon 13)
Sample
not
available
Present Present NCI-Meso21
(Heterozygous
deletion)
Sample not
available
Present Present
Wt- wild-type.
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Additional files
Additional file 1: Short tandem repeat analysis of 5 mesothelioma
primary cells.
Additional file 2: Flow cytometry showing cell surface expression
of mesothelin in early and late passage cells. Cells were incubated
with the anti-mesothelin mAb MN, conjugated with R-PE or isotype control
antibody. Results are shown in terms of histogram plots for each cell line
where the area under the blue line depicts the binding of MN antibody and
the area under the red line shows the binding of isotype control antibody.
Additional file 3: Table S2. Karyotyping of early and late passage
primary mesothelioma cell lines.
Additional file 4: Western blot images showing the expression
E-cadherin, N-cadherin and vimentin in primary cell cultures.
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